Observational studyBMJ open2026
Bailout valve-in-valve therapy during transcatheter aortic valve replacement in bicuspid and tricuspid aortic stenosis: an observational single-centre study in China.
Observational study in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBailout valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) is a critical rescue strategy for procedural failure, yet evidence regarding its outcomes in bicuspid aortic valve (BAV) anatomy remains limited.
methodsThis retrospective, single-centre study analysed 1597 patients (48.3% BAV) undergoing TAVR. Patients were stratified by the requirement for bailout ViV, which was conducted for significant residual aortic regurgitation (AR) or valve embolisation. Predictors were identified via multivariate logistic regression. Early- and mid-term survival outcomes were compared using Inverse Probability of Treatment Weighting (IPTW) via entropy balancing.
resultsBailout ViV was required in 6.20% of patients (BAV: 6.87%; tricuspid aortic valve (TAV): 5.57%). Larger annulus perimeter and significant residual AR after initial deployment were identified as consistent independent predictors of bailout ViV across all cohorts. Additionally, lower annulus calcification volume, non-repositionable self-expanding valves and the learning phase were predictors in the overall cohort. Significant mitral regurgitation and lower calcification volume in BAV and male sex in TAV cohorts were independent risk factors. IPTW-adjusted analysis revealed significantly higher 30-day all-cause (HR 3.09, p=0.019) and cardiovascular mortality (HR 3.49, p=0.021) in the bailout ViV group. However, no significant differences were observed in mid-term all-cause or cardiovascular mortality between groups.
conclusionsBailout ViV was associated with elevated early mortality but offered satisfactory mid-term survival. Key predictors include anatomical challenges (large annulus and insufficient calcification) and procedural factors (non-repositionable self-expanding valve, learning phase TAVR and significant residual AR after the first prosthesis).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.